Parkinson’s Research Questions Answered: Why No Significant Treatments Are Available Yet

Parkinson’s Research Questions Answered: Why No Significant Treatments Are Available Yet

Publication date: Nov 01, 2019

Overview of research timelines and stages; addresses disease modifying therapy research, why past trials have been unsuccessful, and what else is in the pipeline. Given by Kelvin L. Chou MD, at the 2019 University of Michigan Parkinson’s & You Symposium, October 4, 2019

Concepts Keywords
Air Chemical blood
Bass Trial imaging
Biomarker Website search trials
Biomarkers Biomarker imaging
Biomedical Chemical spinal fluid
Blood Leukemia
Brain Dementia
Calcium Channel Blocker Disease
Clinical Endpoint Difference disease
Clinical Trial Progression disease
Clinical Trials Treatment diabetes
Coenzyme Tremor
Cognitive Introduction drug disease
Cohort Diseases
Creatinine Doses effective disease
Dhe Couple trials disease
Dietary Supplement Dietary supplement
Dopa Health
Dopamine Medicine
Double Blind Clinical research
Drug Trial Drugs
DSO Design of experiments
Dso Catecholamines
Emmy Mind–body interventions
Enzyme Clinical trials
Epidemiologic Placebo
FDA L-DOPA
High Blood Pressure Dopamine
Hospital Antibodies
Inflammation
Ing
Inhibitor
Investigational Drug
Keane
Kippers
Leva
Levodopa
Libido
Lille
Ling
Michigan
Milligram
MLB
Nerve Cells
Oxidative Stress
Park
Parkinson
Penarol
Pharmacologic
Physician
Pipeline
Placebo
Plasma
Pop
Primers
Radha
Rating Scale
Recycling
Requip
Rodent
Silver Bullet
Spinal Fluid
Statistical Test
Surveillance
Symptom
Thes
Toxin
Tremor
Trophic Factor
Urine
Vitamin

Semantics

Type Source Name
gene UNIPROT EHD1

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *